Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Merrimack Pharmaceuticals stock

Own Merrimack Pharmaceuticals stock in just a few minutes.

Merrimack Pharmaceuticals, Inc is a biotechnology business based in the US. Merrimack Pharmaceuticals shares (MACK) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Merrimack Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MACK – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Merrimack Pharmaceuticals share price

Use our graph to track the performance of MACK stocks over time.

Merrimack Pharmaceuticals shares at a glance

Information last updated 2021-04-30.
52-week range$3.06 - $9.35
50-day moving average $6.79
200-day moving average $6.25
Wall St. target price$4.00
PE ratio N/A
Dividend yield $1.497 (19.93%)
Earnings per share (TTM) $0.10

Buy Merrimack Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Merrimack Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Merrimack Pharmaceuticals under- or over-valued?

Valuing Merrimack Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Merrimack Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Merrimack Pharmaceuticals's PEG ratio

Merrimack Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.07. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Merrimack Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Merrimack Pharmaceuticals's EBITDA

Merrimack Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $134,000.

The EBITDA is a measure of a Merrimack Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Merrimack Pharmaceuticals financials

Gross profit TTM $-9,100,000
Return on assets TTM -17%
Return on equity TTM -18.18%
Profit margin 0%
Book value $1.20
Market capitalisation $100.7 million

TTM: trailing 12 months

Shorting Merrimack Pharmaceuticals shares

There are currently 369,871 Merrimack Pharmaceuticals shares held short by investors – that's known as Merrimack Pharmaceuticals's "short interest". This figure is 0.7% up from 367,212 last month.

There are a few different ways that this level of interest in shorting Merrimack Pharmaceuticals shares can be evaluated.

Merrimack Pharmaceuticals's "short interest ratio" (SIR)

Merrimack Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Merrimack Pharmaceuticals shares currently shorted divided by the average quantity of Merrimack Pharmaceuticals shares traded daily (recently around 49054.50928382). Merrimack Pharmaceuticals's SIR currently stands at 7.54. In other words for every 100,000 Merrimack Pharmaceuticals shares traded daily on the market, roughly 7540 shares are currently held short.

However Merrimack Pharmaceuticals's short interest can also be evaluated against the total number of Merrimack Pharmaceuticals shares, or, against the total number of tradable Merrimack Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Merrimack Pharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Merrimack Pharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0.0346% of the tradable shares (for every 100,000 tradable Merrimack Pharmaceuticals shares, roughly 35 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Merrimack Pharmaceuticals.

Find out more about how you can short Merrimack Pharmaceuticals stock.

Merrimack Pharmaceuticals share dividends

We're not expecting Merrimack Pharmaceuticals to pay a dividend over the next 12 months.

Have Merrimack Pharmaceuticals's shares ever split?

Merrimack Pharmaceuticals's shares were split on a 1271:1000 basis on 5 September 2019. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1271 shares. This wouldn't directly have changed the overall worth of your Merrimack Pharmaceuticals shares – just the quantity. However, indirectly, the new 21.3% lower share price could have impacted the market appetite for Merrimack Pharmaceuticals shares which in turn could have impacted Merrimack Pharmaceuticals's share price.

Merrimack Pharmaceuticals share price volatility

Over the last 12 months, Merrimack Pharmaceuticals's shares have ranged in value from as little as $3.06 up to $9.35. A popular way to gauge a stock's volatility is its "beta".

MACK.US volatility(beta: 2.29)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Merrimack Pharmaceuticals's is 2.2874. This would suggest that Merrimack Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Merrimack Pharmaceuticals overview

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was founded in 1993 and is headquartered in Cambridge, Massachusetts. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site